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Interleukin-6Hepcidin, a peptide hormone produced in the liver, decreases intestinal iron absorption andmacrophage iron re-
lease via effects on ferroportin. Bone morphogenic protein and Stat3 signaling regulate Hepcidin's transcription.
Hepcidin is a potential drug target for patientswith iron overload syndromes because its levels are inappropriate-
ly low in these individuals. To generate a tool for identifying small molecules that modulateHepcidin expression,
we stably transfected humanhepatocytes (HepG2) cellswith a reporter construct containing 2.7 kb of the human
Hepcidin promoter upstream of a ﬁreﬂy reporter gene. We used high throughput methods to screen 10,169
chemicals in duplicate for their effect on Hepcidin expression and cell viability. Regulators were identiﬁed as
chemicals that caused a change N3 standard deviations above or N1 standard deviation below the mean of the
other chemicals (z-score N3 or b1), while not adversely affecting cell viability, quantiﬁed by ﬂuorescence
assay. Following validation assays, we identiﬁed 16 chemicals in a broad range of functional classes that promote
Hepcidin expression. All of the chemicals identiﬁed increased expression of bone morphogenic protein-
dependent and/or Stat3-dependent genes, however none of them strongly increased phosphorylation of
Smad1,5,8 or Stat3.© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Hepcidin is a cysteine-rich peptide hormone that regulates the ab-
sorption and distribution of iron in humans and other animals [1].
Hepcidin production is transcriptionally regulated in the liver in re-
sponse to body iron stores and inﬂammation [2]. Increases in plasma
iron levels result in enhanced signaling via bone morphogenic proteins
[3] and phosphorylation of Smad1,5, and 8, which facilitates Smad4
binding to the Hepcidin promoter and greater Hepcidin transcription
[4]. The inﬂammatory cytokine, interleukin-6, IL-6, can also upregulate
Hepcidin by activating Stat3 and enhancing Stat3 binding to theHepcidin
promoter [5]. Hepcidin binds ferroportin1, the only known vertebrate
iron exporter, resulting in internalization and degradation of both pro-
teins [6]. Degradation of ferroportin1 decreases intestinal iron absorp-
tion [6] and prevents the release of iron from macrophage iron stores
to developing erythrocytes in the bone marrow [7].ncology, Beth Israel Deaconess
, MA 02215, United States. Fax:
enkel).
. This is an open access article underClinical studies have demonstrated that Hepcidin levels are inappro-
priately low in patients with hereditary diseases associated with iron
overload, such as thalassemia, congenital dyserythropoietic anemia,
and hereditary hemochromatosis [8]. Iron overload is the major cause
of death in patients with thalassemia major [9] and an important
cause of morbidity in transfusion-dependent patients, such as bone
marrow transplant recipients [10]. Current therapies for iron overload
are restricted to chelation or removing blood, phlebotomy [11]. These
therapies are notwell tolerated or completely effective inmany patients
[12]. Intriguingly, transgenic over-expression of Hepcidin in mouse
models of hereditary hemochromatosis [13] or β-thalassemia [14] re-
duces iron overload. Thus, pharmacologically increasingHepcidin levels
may help patients with iron overload by decreasing intestinal iron ab-
sorption. Hepcidin agonists under development include Hepcidin
mimics, such as rationally designed peptides (minihepcidins), and
Hepcidin stimulators, such as anti-sense oligonucleotides directed
against inhibitors of Hepcidin expression, bone morphogenic protein 6
(BMP6) and small molecules therapies that activate the Stat and/or
Smad pathways [12].
Chemical screens are unbiased approaches to identifying small
molecules that affect biological processes. They have been useful in
identifying antagonists of speciﬁc pathways. For instance the bonethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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ﬁed in a chemical screen for small molecules that affect zebraﬁsh em-
bryonic development [15]. Chemical screens identifying small
molecules that impact speciﬁc biological processes have improved our
understanding of these processes and led to clinical trials. For instance,
prostaglandin E2, was shown to be important in hematopoietic stem
cell proliferation [16] and is now being evaluated in human trials to im-
prove the efﬁciency of umbilical cord hematopoietic stem cell trans-
plants [17].
In a preliminary chemical screen evaluating the effect of isoﬂavones
and related compounds in zebraﬁsh embryos and human hepatocytes,
we identiﬁed the small molecule genistein, a phytoestrogen that is
one of the major components of soybeans, as a stimulator of Hepcidin
expression that activated Stat3 and Smad signaling [18]. In order to
identify additional small molecules that act via different mechanisms
and may have greater potency, we undertook a high throughput chem-
ical screen for small molecules that increase Hepcidin expression in
human hepatocytes. To achieve this, we generated a line of human hep-
atoma cells, HepG2 Hepcidin-luciferase, that express 2.7 kb of the
human Hepcidin promoter upstream of a ﬁreﬂy luciferase reporter. We
screened a total of 10,169 small molecules in duplicate for their ability
to increase or decrease Hepcidin expression without impairing cell via-
bility. We validated our hits with quantitative realtime RT-PCR assays
for Hepcidin expression and characterized them by their effects on
genes regulated by BMP's or Stat3, as well as Western blots to detect
phosphorylation of Smad1,5,8 or Stat3. We conﬁrmed 16 small mole-
cule Hepcidin stimulating agents in a broad range of functional classes.
All of the chemicals identiﬁed increased expression of boneFig. 1. A. Effect of positive and negative controls on Hepcidin-luciferase activity in stably trans
transfectedwithHepcidin-luciferasewere treated for 24 hwith DMSO1%, BMP6 50 ng/ml, IL-6 1
sured using the OneGlo Assay (Promega) and is shown as mean fold-change over DMSO-tre
Unpaired Student's t-tests were performed compared to DMSO alone. *** denotes 0.0001 ≤ P
Library Composition. The screening library included known bioactive molecules, molecules
were evaluated for Hepcidin-luciferase activity and viability in HepG2 cells stably transfecte
same assay at three concentrations and in a quantitative realtime RT-PCR assay. D,E. Scatter-p
activity for 343 molecules found to increase (D) or 62 molecules found to decrease (E) Hepcidimorphogenic protein-dependent and/or Stat3-dependent genes, how-
ever none of them strongly increased phosphorylation of Smad1,5,8 or
Stat3. Several of the Hepcidin stimulatory chemicals inhibit growth
factor receptor dependent signaling (AG1296, GTP 14564, AS252424,
10058-F, SU6668, and pterostilbene), decrease inﬂammation
(leﬂunomide, amlexanox), or impair DNA repair and promote apoptosis
(daunorubicin, 9-aminocridine, ethacridine),while the smallmolecules,
vorinostat and SB 204741, inhibit histone deacetylase and serotonin re-
ceptor 2B, respectively. Two of the molecules, ipriﬂavone and
vorinostat, were active at concentrations that were 10-fold below
those required for genistein's effect and thus appear to be intriguing
candidates for further development.
Materials and methods
Cell culture and reagents
The human hepatocarcinoma cell line, HepG2, (American Type Cul-
ture Collection,Manassas, VA)wasmaintained inα-MinimumEssential
Medium (α-MEM)/10% certiﬁed endotoxin-free fetal bovine serum
(FBS)/1% penicillin–streptomycin (Life Technologies, Grand Island,
NY) at 37 °C, 5% CO2. To generate a Hepcidin reporter cell line, HepG2
cells, were transfected using SuperFect (Qiagen, Valencia, CA) transfec-
tion reagent and a reporter construct including a 2.7 kb fragment of the
humanHepcidin promoter upstreamof a ﬁreﬂy luciferase promoter (gift
of Drs. Ganz and Nemeth). Transfected clones were selected for resis-
tance to G418 (Life Technologies) and subsequently maintained in the
conditions described above with the addition of G418 1 mg/ml. Bonefected HepG2 cells. After 16 h of serum starvation in α-MEM/0% FBS, HepG2 cells stably
00 ng/ml, Genistein 10 μM, orDorsomorphin 40 μM.Hepcidin-luciferase activity wasmea-
ated control. The global P-value generated using the Kruskal–Wallis test was b0.0001.
b 0.0009 and ** denotes 0.0009 ≤ P b 0.009. N = 3 biological replicates per condition. B.
of unknown function, and FDA-approved drugs. C. Screening Method. 10,169 chemicals
d with a Hepcidin-luciferase promoter construct. The hits were then re-evaluated in the
lot of structural cluster vs. mean z-score for Hepcidin-luciferase corrected luminescence
n-luciferase activity.
Table 1
Re-screening data on potential agonists or antagonists identiﬁed in the initial chemical
screen. Small molecules that were identiﬁed as potential regulators in the screen were
retested in duplicate at the original concentration screened (Concentration #1) and two di-
lutions (Concentrations #2 and #3) for their effects on Hepcidin-luciferase activity, mea-
sured as fold-change over the activity from cells treated with DMSO only. Candidate
regulators that increased mean Hepcidin-luciferase activity at least 2-fold at the original
concentration were considered agonists (shaded in green), while candidate regulators
that decreased mean Hepcidin-luciferase activity at least 2-fold were considered antago-
nists (shaded in orange).
Regulator name Concen-
tration
#1
(µM)
Hepcidin-
luciferase
activity at
conc. #1
mean+SE
(AU)
N=2
Concen-
tration 
#2
(µM)
Hepcidin-
luciferase
activity at
conc. #2
mean+SE
(AU)
N=2
Concen-
tration 
#3
(µM)
Hepcidin-
luciferase
activity at
conc. #3
mean+SE
(AU)
N=2
Potential agonists
Potential agonists
Vorinostat 33 56.08±35.27 6.6 48.14±6.70 1.3 14.60±4.68
9-Aminoacridine 33 49.76±12.27 6.6 1.14±0.40 1.3 0.68±0.07
Acrisorcin 33 29.85±1.50 6.6 0.99±0.06 1.3 0.77±0.00
Ethacridine 
lactate
33 15.18±1.13 6.6 1.35±0.24 1.3 1.12±0.18
Doxorubicin 12 11.39±0.49 2.4 0.68±0.06 0.5 0.77±0.02
Daunorubicin 12 11.33±0.07 2.4 0.99±0.05 0.5 0.67±0.05
Leflunomide 33 5.50±0.29 6.6 3.10±0.23 1.3 1.12±0.18
#5322770 66 5.03±0.21 12.2 1.42±0.04 2.6 0.84±0.06
Ipriflavone 33 4.57±0.30 6.6 3.41±0.08 1.3 2.56±0.07
Lansoprazole 33 4.09±0.44 6.6 0.98±0.01 1.3 0.58±0.01
Pterostilbene 33 4.06±0.59 16.5 3.91±0.28 8.25 2.21±0.19
Amlexanox 33 3.84±0.95 6.6 2.65±0.06 1.3 0.67±0.02
Nabumetone 33 3.74±0.19 16.5 3.16±0.30 8.25 3.61±0.95
Topotecan 33 3.63±1.39 6.6 0.57±0.05 1.3 0.73±0.04
Camptothecin 33 3.62±0.62 6.6 1.55±0.34 1.3 0.60±0.05
Chrysin 26 3.53±0.60 5.2 1.09±0.11 1.0 0.76±0.01
GTP-14564 11 3.07±0.60 2.2 1.35±0.07 0.4 1.17±0.15
10058-F4 33 2.92±0.23 6.6 2.17±0.01 1.3 1.25±0.13
SB 204741 33 2.87±0.22 6.6 1.96±0.18 1.3 1.09±0.04
Phenazopyridine 26 2.85±0.04 5.2 1.51±0.08 1.0 0.95±0.12
AS-252424 33 2.84±0.02 6.6 1.40±0.03 1.3 0.73±0.02
AG 1296 11 2.41±0.14 2.2 1.03±0.11 0.4 0.90±0.07
SP 600125 33 1.86±0.00 6.6 1.11±0.02 1.3 0.93±0.09
Fenbendazole 22 1.75±0.08 4.4 1.03±0.20 0.9 0.96±0.12
#5105276 66 1.73±0.04 12.2 0.75±0.13 2.6 0.74±0.02
GW9662 33 1.66±0.08 6.6 1.12±0.05 1.3 1.09±0.01
#5102420 66 1.66±0.06 12.2 0.80±0.11 2.6 0.83±0.16
Imatinib 33 1.24±0.13 16.5 1.18±0.06 8.25 1.31±0.06
Nocodazole 22 1.13±0.02 4.4 0.84±0.11 0.9 0.84±0.01
#5193825 66 1.13±0.14 12.2 0.67±0.01 2.6 0.69±0.06
#5215082 66 1.09±0.08 12.2 0.87+0.04 2.6 0.79+0.02
#5146972 66 1.08±0.00 12.2 0.72+0.05 2.6 0.66+0.03
SU-6668 33 0.31±0.02 6.6 0.67+0.09 1.3 0.88+0.01
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interleukin-6 (R&D Systems), and genistein (Sigma-Aldrich, St. Louis,
MO) were used as positive controls for Hepcidin-luciferase activity,
while dorsomorphin (#171260, Calbiochem, Billerica, MA) was used
as a negative control. WP1066 (#573097, Calbiochem) was used as an
inhibitor of Stat3 signaling. Interleukin-6, EGF, FGF, PDGF, and VEGFA
were obtained from R&D Systems.
Chemical screen
The Institute of Chemistry and Cell Biology (ICCB) Screening
Facility at Harvard Medical School provided drug libraries. The
complete list of chemicals screened and the screening data are
provided in Supplementary Table 1. The day before the addition of
compounds, HepG2-Hepcidin luciferase cells were plated at 5000
cells in 30 μl per well of a 384-well microtiter plate (Nunc 142762)
in α-MEM/1% penicillin/streptomycin using a WellMate MicroPlate
Dispenser (Thermo Scientiﬁc, Rockford, IL). Twenty-four hours
later, 100 nl aliquot of chemical was pin-transferred from each
well on the chemical library plate to a corresponding well on
the screening plate. BMP6 (50 ng/ml) was used as a positive
control while vehicle only, DMSO (0.3%), was used as a negative
control. After 24 h of treatment, the cell viability and Hepcidin
promoter activity were measured with the OneGlo + Tox Cell
Viability and Luciferase Reporter assay (E7120, Promega, Madison,
WI) according to the manufacturer's instructions using an EnVision
2102 Plate Reader (PerkinElmer, Waltham, MA). Fluorescence was
measured using an excitation wavelength of 380–400 nm and emis-
sion wavelength of 505 nm. The entire screen was performed in
duplicate.
The primary readout was the crosstalk-corrected Hepcidin lumines-
cence for each well. The secondary readout was cell viability ﬂuores-
cence for each well. For each readout and each well, a z-score was
calculated using the formula: z-score [z = (x − mean of samples on
the plate)/standard deviation of samples on the plate] where x = the
ﬂuorescence or luminescence intensity for the particular well. The pos-
itive and negative controls were excluded from the calculation of the
mean and standard deviation for the plate. An agonist compound was
considered a hit if the luciferase z-scores for both replicates were N3.
An antagonist compound was considered a hit if the luciferase z-score
for each replicate was b−1. Any agonist or antagonist with a cell viabil-
ity ﬂuorescence z-score b−1 on either replicate was excluded from
being considered a hit.
After identifying hits in the screening, we re-screened selected regu-
lators at the original and two additional dilutions using the same lucif-
erase and ﬂuorescence assays. We considered a hit to be validated if it
increased Hepcidin promoter activity at least 2-fold above the vehicle-
only control (1% DMSO) at one of the concentrations. Negative regula-
tors were identiﬁed as those that produced at least a 50% reduction in
Hepcidin promoter activity. Supplementary Table 2 provides the
sources, functional categories, and chemical structures for the candidate
regulators that were characterized further by quantitative realtime RT-
PCR and Western blots.
Quantitative realtime RT-PCR
In order to evaluate whether or not candidate regulators upregulate
Hepcidin via the Stat3 pathway and/or the Smad4 pathway, we plated
400,000 wild type HepG2 cells per well of a 12-well tissue culture
plate. After 8 h of serum starvation in α-MEM/1% FBS, we added each
candidate regulator. After 24 h of treatment, we extracted RNA, and
generated cDNA according to the method [18]. We measured the tran-
script levels of Hepcidin and key genes in each of these pathways in
quantitative realtime RT-PCR using primers and probes as described
(Supplementary Table 3).Western blots
To test for the effects of theHepcidin regulators on proteins involved
with the Smad4 or Stat3 signaling pathways, we plated 400,000 cells in
a 12-well tissue culture plate and changed themedia toα-MEM/1% FBS
for 16 h prior to treating the cells with chemicals for 1 h. The cells were
lysed in radio-immunoprecipitation assay buffer (RIPA buffer) with 1×
Protease Inhibitor/1× Phosphatase Inhibitor Cocktail (both from
Roche). The Pierce BCA Assay (Thermo Scientiﬁc) was used to measure
the protein concentrations. Twenty micrograms of protein lysate was
loaded with 0.5× TruSep SDS Sample Buffer (NuSep Inc., Bogart, GA)
in each lane of a Tris-Glycine 4–10% SDS polyacrylamide gel (NuSep
Inc.). After the gel was run and transferred to a polyvinylidene
diﬂuoride (PVDF) membrane, the membrane was blocked with TBS/
0.05% Tween 20/5% bovine serum albumin for antibodies against phos-
phorylated proteins or Pierce Protein-Free TBS Blocking Buffer (Thermo
Scientiﬁc) for all other antibodies. The primary antibodies, all rabbit
anti-human, were used at the following dilutions: phospho-Smad1, 5,
and 8 (#9511S, Cell Signaling Technology, Inc., Danvers, MA) 1:200,
phospho-Stat3 (SC-8001-R, Santa Cruz Biotechnology Inc., Dallas, TX)
1:100, Smad1 (#9743S, Cell Signaling Technology Inc.) 1:500, Stat3
(#SC-482, Santa Cruz Biotechnology, Inc.) 1:200, or β-actin (#4967S,
Cell Signaling Technology Inc.) 1:1000. The blots were developed with
234 V. Gaun et al. / Blood Cells, Molecules and Diseases 53 (2014) 231–240secondary antibody, mouse anti-rabbit IgG-horseradish peroxidase
(#SC-2357, Santa Cruz Biotechnology Inc.) 1:5000, followed by addition
of Pierce ECL Western Blotting Substrate (Thermo Scientiﬁc) according
to the manufacturer's instructions. The blots were exposed to Kodak
Biomax light ﬁlm (Sigma-Aldrich) for 5–30 min at room temperature.
Statistical analysis
Graphs were created and statistical analyses were performed using
Prism 6.0c (Graphpad, San Diego, CA). We used the Kruskal–Wallis
method to generate a global P-value for each experiment. Where the
global P-value was b0.05, Student's t-tests were performed. P b 0.05
was considered a signiﬁcant result on the Student's t-test.
Structural analysis of small molecules
To assess patterns of structural similarity, the structures of all the
compounds producing an average crosstalk corrected Hepcidin-
luciferase z-score N3 or b−1, regardless of effects of viability were ana-
lyzed. The 405 compound structures were imported into Vortex
(Dotmatics, Inc., version 2012.07.15406) and a 1024-bit Dotmatics
hex-packed ﬁngerprint was generated. Compounds were clustered on
the basis of this ﬁngerprint using Rogers–Tanimoto similarity, leading
to 57 structural clusters (378 compounds) plus 27 singleton compounds
that were not included in any of the clusters.
Results
In order to evaluate the effects of a broad range of small molecules
on Hepcidin expression, we screened 10,169 chemicals in a dualFig. 2. Quantitative realtime RT-PCR for A. Hepcidin, B. ID3, and C. SOCS3. Following 8 h of seru
DMSO 1%, BMP6 100 ng/ml, IL-6 100 ng/ml, dorsomorphin (an inhibitor of BMP signaling) 10
ipriﬂavone 1 μM, doxorubicin 10 μM, daunorubicin 10 μM, pterostilbene 10 μM, AS252424 3
33 μM, camptothecin 33 μM, chrysin 33 μM, 10058-F4 33 μM, phenazopyridine 33 μM, leﬂuno
quantitative realtime RT-PCR. Data shown are means ± SE's. N = 3–6 biological replicates pe
each experiment. Unpaired Student's t-tests were performed compared to DMSO alone. * de
****P b 0.0001. D. Venndiagram illustratingwhich chemicals appear to increase RNA transcript l
script, SOCS3.Hepcidin luciferase assay and viability assay. The screening assays
were performed in HepG2 cells stably transfected with a human
Hepcidin promoter fragment (2.7 kb) upstream of a ﬁreﬂy luciferase re-
porter. Hepcidin-luciferase activity in treated cells was measured as
fold-change over controls treated with vehicle only (DMSO ≤1%). We
conﬁrmed that treatment for 24 h with positive controls, BMP6
50 ng/ml, IL-6 100 ng/ml, or genistein 10 μM, signiﬁcantly increased
Hepcidin-luciferase activity in the stably transfected cells (2378 ±
185.4, 3.48 ± 0.24, 2.64 ± 0.28, respectively), while dorsomorphin 40
μM decreased it (0.59 ± 0.35) (Fig. 1A).
The composition of the library screened (Fig. 1B) included a diverse
range of chemicalswith themajority knownbioactives (7496), followed
by molecules of unknown function (2112), and FDA-approved drugs
(561). To each well, 100 nl of a single small molecule was transferred
prior to incubation of the cells at 37 °C for 24 h. The entire screen was
performed in duplicate. Of the 10,169 chemicals originally screened,
343 agonists and 62 antagonists were initially identiﬁed by producing
a z-score N3 or b−1 for Hepcidin expression, respectively (Fig. 1C).
Analysis of these chemicals with the Vortex program separated these
chemicals into 57 structural groups. Agonists (Fig. 1D) and antagonists
(Fig. 1E) were scattered across the structural groups without a domi-
nant structure. When toxic chemicals were excluded by eliminating
compounds that produced a z-score for viability b−1, i.e. b1 standard
deviation reduction in cell viability, 30 agonists and 3 antagonists
remained.We re-screened thesemolecules at the original concentration
and at 2 dilutions in duplicate. Of these chemicals, 22 agonists and 1 an-
tagonist were conﬁrmed on re-screening (Table 1).We did not evaluate
acrisorcin further, because it is a salt of 9-aminoacridine with 4-
hexylresorcinol [19], that produced a similar effect to 9-aminoacridine,
one of the other Hepcidin stimulating agents (Table 1). We also didm starvation in α-MEM/1%FBS, HepG2 cells were treated for 24 h in α-MEM/1%FBS with
μM, GTP 14564 5 μM, AG1296 5 μM, SU6668 10 μM, nabumetone 5 μM, vorinostat 1 μM,
3 μM, ethacridine lactate 33 μM, amlexanox 33 μM, lansoprazole 33 μM, topotecan HCl
mide 33 μM, 9-aminoacridine 33 μM, and SB-204741 33 μM. RNA was then extracted for
r treatment. The global P-value generated using the Kruskal–Wallis test was b0.0001 for
notes 0.009 ≤ P b 0.05, ** denotes 0.0009 ≤ P b 0.009, *** denotes 0.0001 ≤ P b 0.0009,
evels ofHepcidin and the BMP-dependent transcript, ID3, and/or the Stat3-dependent tran-
Fig. 3. A–C. Effect of AG1296 and GTP 14564 on transcript levels of ID1(A), IL6 receptor (B), and VEGFA (C). HepG2 cells were treated with chemicals at the same doses and with the same
conditions as described in Fig. 2. Data shown aremeans± SE's. N=3–6 biological replicates per treatment. The global P-value generated using the Kruskal–Wallis testwas b0.0001 for ID1
and =0.01 for IL6R and VEGFA. Unpaired Student's t-tests were performed compared to DMSO alone. * denotes 0.009 ≤ P b 0.05, ** denotes 0.0009 ≤ P b 0.009, *** denotes 0.0001 ≤ P
b 0.0009, ****P b 0.0001. D. Effect of AG1296 or GTP 14564 on Hepcidin-Luciferase Activity in the presence or absence of growth factors or FLT3. After 16 h of serum starvation in α-
MEM/0% FBS, HepG2 cells stably transfected with Hepcidin-luciferase were treated for 24 h with AG1296 (5 μM) or GTP 14564 (5 μM) in the presence or absence of EGF 150 ng/ml,
FGF 200 ng/ml, PDGF 50 ng/ml, VEGF 150 ng/ml, or FLT3 150 ng/ml. Hepcidin-luciferase activity was measured using the OneGlo Assay (Promega) and is shown as mean fold-change
over DMSO-treated control. The global P-value generated using the Kruskal–Wallis test was b0.0001. Unpaired Student's t-testswere performed. ** denotes 0.0009≤ P b 0.009, compared
to DMSO-treated control. ++ denotes 0.0009≤ P b 0.009, compared to AG1296-treated cells. # denotes 0.009 ≤ P b 0.05, compared to GTP 14564-treated cells. ## denotes 0.0009 ≤ P
b 0.009, compared to GTP 14564-treated cells. N = 5–9 biological replicates for each condition.
235V. Gaun et al. / Blood Cells, Molecules and Diseases 53 (2014) 231–240not evaluate #532270 further because it was only moderately active
(5.03 ± 0.21) at 66 μM and weakly active (1.42 ± 0.04) at 12 μM.
The remaining twenty potential Hepcidin agonists and one antago-
nist were subsequently evaluated by quantitative realtime RT-PCR for
Hepcidin expression at the same concentrations that were effective in
theHepcidin-luciferase assay. BMP6 and dorsomorphin, used as positive
and negative controls, respectively, produced the expected effects on
Hepcidin expression (Fig. 2A). Sixteen of the 20 putative agonists signif-
icantly increased Hepcidin transcript levels, however, the putative ago-
nists, topotecan, campthothecin, nabumetone, and chrysin, failed to
increase Hepcidin transcript levels, despite increasing Hepcidin-
luciferase activity, while the putative antagonist, SU6668, increased
Hepcidin transcript levels, despite decreasing Hepcidin-luciferase
activity.
In previous RNA sequencing and quantitative RT-PCR experiments
[18], we had identiﬁed the BMP-regulated transcript, ID3 [20–22], and
the Stat3-regulated transcript SOCS3 [23], as genes whose expression
increased signiﬁcantly in HepG2 cells following treatment with BMP6
or IL-6, respectively. Thus, we evaluated the effects of the chemicals
on ID3 (Fig. 2B) and SOCS3 (Fig. 2C) transcript levels, as readouts for
bonemorphogenic protein signaling and Stat3 signaling [18]. As expect-
ed, BMP6 produced a signiﬁcant increase in ID3 expression over DMSO
alone (16.17 ± 1.57, P b 0.0001) that was not observed with IL-6treatment, while IL-6 increased SOCS3 expression (3.88 ± 0.59, P =
0.0002), but BMP6 did not. The BMP receptor antagonist, dorsomorphin,
used as a negative control, inhibited ID3 expression (0.48 ± 0.16, P
b 0.0001).
The HDAC inhibitor, vorinostat, which was one of the most
potent Hepcidin stimulating chemicals identiﬁed in the screen, pro-
duced a particularly strong increase in Hepcidin (15.09 ± 0.55, p
b 0.0001) and ID3 expression (10.3 ± 0.33, P b 0.0001). The majority
of chemicals that signiﬁcantly upregulated Hepcidin transcript levels
signiﬁcantly upregulated ID3, with the exception of daunorubicin,
ethacridine, and 9-aminoacridine, which either decreased or did not af-
fect ID3 expression (Fig. 2B). Interestingly, theHepcidin agonists that did
not upregulate ID3, did upregulate SOCS3, consistent with Stat3
pathway activation (Fig. 2C). Thus the Hepcidin agonists can be
divided into three classes: (1) upregulators of BMP signaling only, (2)
upregulators of Stat3 signaling only, and (3) upregulators of both
pathways (Fig. 2D).
We were particularly interested in the kinase inhibitors, GTP 14564,
AG1296, and SU6668, since they each affect growth factor dependent
signaling, which has previously been shown to affect Hepcidin expres-
sion [24]. GTP 14564 inhibits FLT3, c-Fms, c-Kit, and PDGFRβ [25],
while AG1296 impairs signaling by both PDGF-α and β receptors and
by c-Kit [26]. SU6668 has broad effects against receptor tyrosine kinases
Fig. 4.Western blots. Following 16 h of serum starvation inα-MEM/1%FBS, HepG2 cells were treated for 1 h inα-MEM/1%FBS with the chemicals at the same concentrations as given in
Fig. 2. Proteinwas extracted from the cells, separated by SDS-PAGE, and blotted for incubationwith antibodies against anti-P-Smad1,5,8 (A) or P-Stat3 (B). Following immunoblotting, the
membraneswere stripped and re-probedwith either antibody against anti-Smad1,5,8 (A) or Stat3 (B). The blotswere then stripped again and probed for β-actin as a loading control. Each
chemical was evaluated in two or three biological replicates.
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classiﬁcation of these compounds by ID3 and SOCS3 expression
(Figs. 2B–D), we evaluated these chemicals for their effects ontranscription of an additional BMP-dependent gene, ID1 [20–22], and
additional Stat3-dependent genes [23,18], IL6 receptor (IL6R) and
VEGFA. We found that GTP 14564 and SU6668 each signiﬁcantly
237V. Gaun et al. / Blood Cells, Molecules and Diseases 53 (2014) 231–240upregulated expression of ID1, as well as IL6R and VEGFA (Figs. 3A–C).
Although AG1296 did not signiﬁcantly increase expression of ID1, it
did signiﬁcantly increase transcript levels of BMP and Stat3-
dependent genes, including ID3 (Fig. 2B), SOCS3 (Fig. 2C), and VEGFA
(Fig. 3C). Thus it appears that these growth factor receptor tyrosine ki-
nase inhibitors upregulate both the BMP and Stat3 signaling pathways.
To assess the effects of growth factors onHepcidin promoter activity,
we treated the Hepcidin-Luciferase HepG2 cells with EGF 150 ng/ml,
FGF 200 ng/ml, PDGF 50 ng/ml, VEGF 150 ng/ml, or FLT3 150 ng/ml
for 24 h in the presence or absence of the tyrosine kinase inhibitors,
AG1296 (5 μM) or GTP 14564 (5 μM) (Fig. 3D). We found that each of
these proteins signiﬁcantly reduced baselineHepcidin promoter activity.
In combinationwith GTP 14564 each of the tested proteins signiﬁcantly
impaired GTP 14564's stimulation of Hepcidin promoter activity, while
in combination with AG1296, only EGF, FGF, or FLT3 signiﬁcantly
blocked AG1296's induction ofHepcidin promoter activity. Thus growth
factor- or FLT3-dependent signaling appears to inhibitHepcidin promot-
er activity and to impair the stimulatory effects of AG1296 and GTP
14564, but we did not observe a phenomenon that was limited to one
particular growth factor or ligand.
We had hypothesized that the Hepcidin stimulatory molecules iden-
tiﬁed in the screen would increase phosphorylation of Smad1,5, and 8
and/or phosphorylation of Stat3. To evaluate this hypothesis, we per-
formed Western blots to evaluate the ratio of P-Smad1,5,8 to Smad1
(Fig. 4A) and P-Stat3 to Stat3 (Fig. 4B). As expected, BMP6 treatment in-
creased the intensity of P-Smad1,5,8 relative to Smad1 after 1 h of treat-
ment, however, none of the small molecules signiﬁcantly increased the
intensity of P-Smad1,5,8 relative to Smad1, as assessed by densitometry.
Furthermore, in the one hour time frame, neither IL-6 nor any of the
small molecules tested increased the intensity of P-Stat3 relative to
Stat3. WP1066, a known inhibitor of Jak2 and Stat3 phosphorylation
[28] for Jak/Stat signaling, did not decrease P-Stat3 to Stat3, however
WP1066 is reported to be more effective after 24–48 h of incubation
[28]. After 24 h of treatment, we observed a signiﬁcant increase in
Stat3 protein levels relative to DMSO-treated controls in the hepato-
cytes treated with lansoprazole or vorinostat (2.34 ± 0.96, P = 0.047
and 1.88 ± 0.43, P = 0.03, respectively, Supplementary Fig. 1), but no
signiﬁcant change in phosphorylation of Stat3 relative to Stat3 levels.Discussion
In this study, we have demonstrated a high throughput screening
method to identify small molecules that regulate Hepcidin gene expres-
sion using aHepcidin-luciferase reporter cell line. Our studywas the ﬁrst
large-scale screen for small molecules upregulating Hepcidin transcript
levels. Using a screening approach that includes toxicity evaluation,
we have identiﬁed the largest number of non-toxic small molecules
that stimulate Hepcidin, which will facilitate future preclinical studies
in iron overload syndromes. Several of the Hepcidin stimulating agents
thatwe identiﬁed are drugs that are orally bioavailable or have been ap-
proved by the United States Food and Drug Administration (FDA) for
other indications. These factors will facilitate their testing in preclinical
models. The FDA-approved drugs that we identiﬁed include amlexanox,
lansoprazole, leﬂunomide, vorinostat, and phenazopyridine, while
pterostilbene and isoﬂavone are already commercially available as nu-
tritional supplements. Small scale screening efforts previously identiﬁed
genistein [18] and three kinase inhibitors [24] as small molecules
that stimulate Hepcidin expression. Peptide analogs of hepcidin,
minihepcidins, have also been injected into Hepcidin-deﬁcient mice to
prevent iron overload [29], but are not orally available. High throughput
screening has previously been used to identify small molecules that
function as Hepcidin antagonists, but not agonists [30]. Other antago-
nists to Hepcidin that have been developed include an antibody to
Hepcidin [31], soluble hemojuvelin [32], and the bone morphogenic
protein receptor antagonists, dorsomorphin and LDN-193189 [32].Having screened 10,169 molecules, we identiﬁed 33 potential hits,
which were reduced to 21 after re-screening with the same assay. Fur-
ther characterization with quantitative realtime RT-PCR for Hepcidin
transcript level reduced the number of hits to 16 agonists and no antag-
onists. Of the publically available small molecule screens in PubChem,
20% rely on bioluminescent assays, such as ours [33]. A recent study of
360,864 compounds in the NIH Molecular Libraries Small Molecule Re-
pository revealed that 12% of the library inhibits ﬁreﬂy luciferase [34].
Interestingly, some of these inhibitors can prolong the half-life of the
ﬁreﬂy luciferase enzyme causing an increase in bioluminescence,
which can be misinterpreted as increased transcriptional activation of
the gene [35–37]. Another possibility, is that the discrepancies between
ﬁndings in the Hepcidin luciferase assay and the Hepcidin quantitative
realtime RT-PCR assay are caused by the absence of distal elements in
the 2.7 kb fragment of the Hepcidin promoter-Luciferase construct that
are present in the endogenous Hepcidin promoter. For these reasons,
we believe that it is not surprising that 24% of the 21 hits that we iden-
tiﬁed did not produce the anticipated effect onHepcidin transcript levels
in the quantitative RT-PCR assay.
In our previous work, we identiﬁed genistein as a small molecule
that increases Hepcidin expression in human hepatocytes and zebraﬁsh
embryos by activating both bonemorphogenic protein and Stat3 signal-
ing pathways [18]. Genistein strongly upregulated transcript levels of
ID3 and SOCS3 [18], BMP- and Stat3-dependent genes, respectively,
thus we assayed for effects on expression of these genes as a short-
hand for BMP and Stat3-dependent gene expression associated
with treatment by the hits identiﬁed in the screen. We found that all
the hits that increased Hepcidin expression in the screen upregulated
one or both of these genes (Figs. 2A–C). Thus we were able to classify
the hits by their association with BMP or Stat3 signaling pathways
(Fig. 2D).
Interestingly, none of the chemicals tested caused enhanced phos-
phorylation of Smad1,5,8 or Stat3. While Western blots for P-
Smad1,5,8 appeared to be highly sensitive, indicating a clear increase
in P-Smad1,5,8 signal to Smad1 for hepatocytes treated with BMP6
(Fig. 4A), Western blots for PStat3 to Stat3 (Fig. 4B) were less sensitive
and unable to detect the 3-fold increase in PStat3 to Stat3 that we had
previously observed with an ELISA assay [18] performed on HepG2
cells treated with IL-6 for at the same concentration and conditions
used in these experiments. Thus it is possible that the chemicals activat-
ed Stat3 at a level that was below the limit of detection for this assay.
We did observe, however, that Stat3 protein levels signiﬁcantly in-
creased in hepatocytes after 24 h of treatment with lansoprazole or
vorinostat (Supplementary Fig. 1). It appears likely that the chemicals
either potentiated or stabilized Smad or Stat3 binding to the Hepcidin
promoter without increasing phosphorylation of the proteins, caused
phosphorylation at a later time point, whichwouldmost likely be an in-
direct effect after other signal transduction cascades were activated, or
acted via other pathways.Potent agonists
The twomost potent agonists, ipriﬂavone and vorinostat, active at 1
μMconcentrations, were 10-foldmore potent than genistein [18]. Inter-
estingly, ipriﬂavone, like genistein, is an isoﬂavone with estrogenic
properties [38]. Ipriﬂavone is used to treat osteoporosis based on its
ability to inhibit osteoclast activity, promote mineralization of osteo-
blasts [39], and increase bone mineral density in postmenopausal
women [40]. However, our previous work indicated that estradiol
does not increaseHepcidin expression and that blockade of the estrogen
receptor fails to inhibit genistein's effect on Hepcidin expression [18],
thus we think it is unlikely that ipriﬂavone is promoting Hepcidin ex-
pression in an estrogenic manner. Similar to our observation of genis-
tein [18], ipriﬂavone increased expression of the BMP-dependent
gene, ID3 (Fig. 2B), however, unlike genistein, ipriﬂavone did not
Fig. 5. Schematic illustrating the pathways implicated in transcriptional regulation of Hepcidin by the small molecules identiﬁed asHepcidin stimulators in the screen.→ indicates a stim-
ulatory effect, while ⊣ indicates an inhibitory effect.
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crease Stat3 phosphorylation (Fig. 4B).
Tyrosine kinase inhibitors
Several of the hits that increased Hepcidin transcript levels were ty-
rosine kinase inhibitors affecting growth factor signaling (Fig. 5), includ-
ing SU6668, GTP 14564, and AG1296. SU6668 inhibits VEGF, FGF, and
PDGF receptors [27]. We found that SU6668 exhibited the paradox-
ical effect of inhibiting Hepcidin-luciferase activity, but increasing
Hepcidin transcript levels in the quantitative realtime RT-PCR ex-
periments. GTP 14564 and AG1296, however, both increased
Hepcidin-luciferase activity and Hepcidin transcript levels in quan-
titative realtime RT-PCR assays. GTP 14564 is a potent inhibitor of
FLT3, c-Fms, c-Kit, and PDGFRβ [25], while AG1296 inhibits signal-
ing by both PDGF-α and β receptors and by c-Kit, without affecting
VEGF receptor signaling [26]. We demonstrated that AG1296 or
GTP 14564's stimulatory effects on the Hepcidin promoter can be
signiﬁcantly impaired by co-treating with EGF, FGF, or FLT3 (for
AG1296 or GTP 14564) or PDGF or VEGF (for GTP 14564). Both
PDGF-α and β receptors signal via PI3 Kinase, among other path-
ways, and can activate Src leading to transcription of c-Myc [41].
Two of the other Hepcidin stimulating agents that we identiﬁed in
the screen, AS252424 and 10058-F4, affect pathways that can act
downstream of PDGF receptor. AS252424 inhibits PI3 Kinase
isoform γ [42], while 10058-F4 blocks c-Myc's activity [43,44].
Interestingly, pterostilbene, another Hepcidin agonist that we iden-
tiﬁed in the screen, is a naturally occurring polyphenolic anti-
oxidant compound that has been shown to inhibit human growth
factor signaling via PI3 Kinase in breast cancer cells and PDGF-
driven proliferation in vascular smooth muscle cells [45].
To facilitate high throughput screening, we performed our screen
entirely in human hepatoma cells (HepG2). As hepatocellular carcino-
ma cells exhibit increased signaling by FGF, PDGF, and VEGF, this may
have biased our results to identify antagonists of growth factor signal-
ing. Others, however, have used small scale screening of kinase inhibi-
tors to demonstrate that hepatocyte growth factor (HGF) and
epidermal growth factor (EGF) reduce BMP-stimulated Hepcidin ex-
pression in a mitogen-activated ERK kinase/extracellular signal-related
kinase (MEK/ERK) dependent manner in primary mouse hepatocytes[24]. HGF's inhibitory activity onHepcidin expression can be suppressed
by pre-treatment with small molecule inhibitors of Met (PHA665752),
MEK1/2 (U0126), or PI3Kinase (LY2940021) [24]. Furthermore intra-
peritoneal injection of EGF in wild type mice reduces the induction of
Hepcidin expression in response to iron loading [24]. Given these ﬁnd-
ings, we propose that SU6668, GTP 14564, AG1296, AS252424, 10058-
F, and pterostilbene enhance Hepcidin transcript levels in HepG2 cells
by inhibiting growth-factor dependent signaling.
HDAC inhibitors
One of the most interesting ﬁndings in the screen is that the nonse-
lective histone deacetylase (HDAC) inhibitor, vorinostat, is a potent
stimulant of Hepcidin expression. These data are consistent with the
ﬁnding that histone acetylation increases Hepcidin expression [4,46,
47]. In particular, post-translational modiﬁcation of Histone H3, one of
the core proteins of the nucleosome, regulates transcription and chro-
matin condensation [48]. Transfection of Smad4 into Smad4-null hepa-
tocytes increases binding of Histone 3 acetylated at lysine 9 (H3K9) to
the Hepcidin promoter [4]. Histone acetylation also appears to affect
Stat3 binding to theHepcidin promoter. Hepatitis C viral infection of cul-
tured hepatoma cells causes hypoacetylation of histones and decreased
Hepcidin expression, while treatment with the pan-HDAC inhibitor,
trichostatin A, increases Stat3 binding to the Hepcidin promoter [46]
and enhances Hepcidin expression [46,47]. Vorinostat has been ap-
proved for the treatment of refractory cutaneous T-cell lymphoma
[49] and thus may be amenable to clinical investigation in patients
with iron overload syndromes who produce inappropriately low levels
of Hepcidin.
Drugs that increase ID3 expression
The anti-inﬂammatory drugs, amlexanox, lansoprazole, and
leﬂunomide each increased Hepcidin expression and ID3 expression in
the screen. Amlexanox is an anti-allergic drug that binds the cytoskele-
tal protein S100A13 and inhibits heat shock-induced release of FGF1
[50]. Lansoprazole, a drug commonly used to treat stomach ulcers, in-
hibits the H+/K+-adenosine triphosphatase in gastric parietal cells,
but it also has been shown to have anti-inﬂammatory properties, in
the esophagus, intestine, and lung and can stimulate heme oxygenase-
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arthritis, yields an active metabolite, A771726, which potently blocks
pyrimidine synthesis by inhibiting dihydroorotate synthase. At higher
concentrations, however, such as those used in this study, leﬂunomide
inhibits phosphorylation of PDGF receptor or EGF receptor (IC50 30–55
and 150–200 μM, respectively) [52].
The chemical screen described here also demonstrated a potential
role for serotonin receptor 2B in regulating Hepcidin expression. We
found that SB 204741, a serotonin receptor 2B (5-HT2B) antagonist, in-
creased Hepcidin expression and ID3 expression. Serotonin stimulates
proliferation of hepatocellular carcinoma cells [53], but represses liver
regeneration via effects on hepatocyte stellate cells [54]. Animal studies
indicate that the 5-HT2B inhibitor, SB 204741, confers the converse ef-
fect, decreasing growth of human hepatocellular carcinoma xenografts
inmice [53], but enhancing liver regeneration followingpartial hepatec-
tomy in animal models [54].
Drugs that increase SOCS3 expression
Daunorubicin, ethacridine lactate, phenazopyridine, and 9-
aminoacridine each increased Hepcidin transcript levels and expression
of the Stat3-dependent gene, SOCS3. As Stat3 is critically involved in
liver injury and regeneration [55], it may be that these drugs stimulate
Hepcidin expression by facilitating cell injury. Daunorubicin is an anti-
cancer drug and DNA intercalator that inhibits Topoisomerase II
resulting in breaks in double stranded DNA and increased apoptosis
[56]. Daunorubicin has also been shown to increase expression of
Stat3-dependent genes, such as SOCS3 [57]. Ethacridine lactate pro-
vokes uterine contractions and histamine release [58], but also inhibits
poly(ADP-ribose) glycohydrolase [59], the major enzyme that catabo-
lizes poly(ADP-ribose). Inhibition of poly(ADP-ribose) glycohydrolase
has been shown to promote apoptosis and impair DNA repair in cells
damaged by oxidative stress [60]. Phenazopyridine can cause liver inju-
ry [61,62], while 9-aminoacridine is a DNA intercalator and experimen-
tal mutagen [63].
Conclusions
As a result of our screen, we have identiﬁed 16 small molecules that
increase Hepcidin transcript levels in human HepG2 cells. Several of
these chemicals affect growth factor receptor signaling, have anti-
inﬂammatory properties, or impact DNA repair and apoptosis. The iden-
tiﬁcation of multiple inhibitors of growth factor receptors and their
downstream targets (Fig. 5) indicates the importance of this pathway
in regulating Hepcidin expression, while the discovery of inhibitors of
histone deacetylase and serotonin receptor as Hepcidin stimulating
agents indicates newavenues for further study.While each of these can-
didate molecules was associated with increases in transcript levels of
other BMP and/or Stat3 associated genes, none of them exhibited a
strong effect on Smad1,5,8 or Stat3 phosphorylation. Further studies
will be needed to determine how each of these different molecules
functions to increase Hepcidin transcript levels. We also plan experi-
ments to determine if these chemicals are effective in raising Hepcidin
levels in vivo. In the future, we would like to test these candidate
Hepcidin stimulatory chemicals in animalmodels of iron overload tode-
termine if they could be adapted into therapeutic agents for patients
with iron overload syndromes.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bcmd.2014.06.002.
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